Articles
Plain explanations of what these assessments measure, written for the person having them and for the clinician reading the report.
-
B Vitamins in Mild Cognitive Impairment: Measure Before It Is Late
B vitamins slowed atrophy in mild cognitive impairment and failed in Alzheimer’s disease. What that means for testing older patients, drug-related B12 loss, and screening workflow.
-
Metformin B12 Deficiency: Screening Beyond the Serum Level
Serum B12 undercalls tissue-level deficiency, and metformin users carry the most risk. The cohort and trial evidence, what a functional marker changes, and how to build it into standing orders.
-
Methylmalonic Acid Test: When a Normal B12 Is Not Enough
A B12 inside the normal range can still hide a shortfall at the level of your cells. What the methylmalonic acid test measures, who is most at risk, and what to ask for.
-
Statins and Dementia: Measuring Cognition in Patients on Statins
Trials show no cognitive harm on average; a reversible effect in a susceptible few is testable only against a baseline. The evidence and a measurement protocol.
-
Statins and Memory Loss: What to Measure Before Anyone Guesses
The brain makes its own cholesterol behind a barrier your lipid panel never sees. What the statin memory evidence shows, and how a cognitive baseline makes it testable.
-
Insulin Resistance and Dementia: Screening Past the Glucose
Glucose and A1c record the failure of compensation, not its onset. The evidence on insulin resistance and dementia, who to screen, and what a finding changes.
-
Fasting Insulin Screening: The Gate on the Brain’s Second Fuel
Glucose is a late marker. Why fasting insulin and related measures belong in screening, what thresholds the literature supports, how to interpret ketones safely, and how to route results into the chart.